长风药业股份有限公司 (Cf Pharmtech Inc.) (中国)

The company was incorporated in the People's Republic of China (“PRC”) on 24 January 2013 as a limited liability company. The company are mainly engaged in the research and development of respiratory drugs and other related medical products
The company are mainly engaged in the research and development of respiratory drugs and other related medical products
HISTORY
2007 - Jiangyin CF, the company predecessor, was established to carry out R D of inhalation drugs
2013 - Company was established in the PRC as a limited liability company
2015 - The company commenced the R D of CF018 in January
2017 - The company completed Series D Financing and introduced FIIF as company pre - IPO Investor in August
2018 - The company GW008 was acknowledged as a “National Innovative Drug Development Project” by the NHC in November
2019 - The company launched the phase III clinical trial of CF018 in China in January
2021 - The company obtained NMPAapproval for CF017 in May, marking company first product approval, and CF017 was included in the first batch of VBP scheme for
eight provinces in China in June
- The company obtained the NMPA approval for CF036 in October, marking company first approved SABA product
2022 - The company obtained the NMPA approval for company CF018 in November
2023 - The company CF018 was included in the NRDL list in December
- The company obtained the NMPA approval for CF038 in September, marking company second approved SABA product
2024 - The company obtained the FDA approval for company GW006 in May, marking company first approved product in the United States
2025 - The company obtained the NMPA approval for company CF022 in January